Type 2 diabetes drug Byetta helped usher in a new class of drugs aimed at helping improve blood sugar control that worked differently than drugs on the market at the time. Some clinical researchers said that the glucagon-like peptide-1 receptor agonist changed the landscape of diabetes treatment completely.
While Byetta was a very different drug when it was introduced in 2005, hundreds of patients taking the medication since its debut have experienced unforeseen side effects of pancreatitis and pancreatic cancer. Many were hospitalized for their symptoms, and some even died of the complications researchers have linked to the diabetes drug.
Due to the previously unknown side effects, patients have filed lawsuits against the maker of Byetta with claims that the company hid the risks from the public, failed to test Byetta’s safety properly, and made a defective drug.
Nearly a thousand cases against Byetta and similar type 2 diabetes drugs are currently pending in a federal court in California. Learn more about Byetta and what the lawsuits claim.